ALS expands Life Sciences service offering and geographic footprint with acquisition of 49% stake in European Pharmaceutical business.
ALS Limited (ASX: ALQ), a leading global testing, inspection and certification business, today announced the acquisition of an initial 49% interest in NUVISAN, a pharmaceutical testing business with operations in Germany and France.
Founded in 1979, NUVISAN is privately owned with over 1,000 employees and generated
~EUR185 million of revenue and
~EUR40 million of adjusted EBITDA in FY21.
NUVISAN operates in contract research organisation (CRO) and contract development and manufacturing organisation (CDMO) markets providing drug testing services throughout the pharmaceutical development cycle in the fast-growing outsourced market.